Close

Glycan-specific IgM is critical for human immunity to Staphylococcus aureus

Astrid Hendriks, Priscilla F. Kerkman, Meri R.J. Varkila, Jelle L.G. Haitsma-Mulier, Sara Ali, Thijs ten Doesschate, Thomas W. van der Vaart, Carla J.C. de Haas, Piet C. Aerts, Olaf L. Cremer, Marc J.M. Bonten, Victor Nizet, George Y. Liu, Jeroen D.C. Codée, Suzan H.M. Rooijakkers, Jos A.G. van Strijp, Nina M. van Sorge

Posted on: 10 August 2023 , updated on: 11 August 2023

Preprint posted on 16 July 2023

Move over IgG: WTA-specific IgM is unexpectedly good at targeting Staphylococcus aureus

Selected by Lucy Bowden

Categories: immunology, microbiology

Background

Staphylococcus aureus, a bacterial pathogen, is responsible for numerous community- and hospital-acquired infections, many of which are caused by antibiotic-resistant strains. The growing challenge of antibiotic resistance necessitates the exploration of alternative approaches to improve clinical outcomes in treating bacterial infections.

Neutrophils are immune cells that phagocytose invading bacteria. To facilitate their recognition and engulfment of these pathogens, additional immune factors such as antibodies and complement proteins act as opsonins, marking the bacterium for phagocytosis. Despite extensive efforts, the identification of opsonizing IgG antibodies targeting S. aureus has been met with limited success in human clinical trials. This might be due to a protein found on S. aureus, staphylococcal protein A (SpA), which inhibits the efficacy of IgG opsonization. However, IgG antibodies are not the sole contributors to enhanced neutrophil activity. IgM antibodies may be able to not only bind S. aureus but also remain unaffected by SpA. Up to this point, research focused on IgM antibodies has been relatively limited since they are conventionally considered to be merely undifferentiated prototype antibodies.

 

Summary

WTA-specific IgM antibodies were more effective than IgG antibodies in vitro

In this study, the researchers utilized synthetic S. aureus wall teichoic acids (WTAs) to study how different kinds of antibodies target the three WTA glycotypes found in S. aureus. WTAs are conserved cell-wall anchored glycopolymers that are a target for opsonizing antibodies. The plasma of healthy donors was found to contain IgM antibodies that bound to all three WTA glycotypes. Next, the researchers compared the efficiency of both IgM and IgG antibodies and found that the IgM variant was over 100-fold more effective than the IgG variant at inducing complement deposition on S. aureus. They also found that the presence of SpA did not interfere with IgM-mediated complement deposition. This complement deposition triggered neutrophil-mediated killing of S. aureus in the presence of IgM antibodies but did not occur in the presence of IgG antibodies.

WTA-specific IgM antibodies were more effective than IgG antibodies in mice

Next, the researchers passively immunized mice with WTA-specific IgM prior to S. aureus infection. The IgM-treated mice had significantly lower CFU counts of bacteria in their spleens as compared to control groups treated with PBS or a non-specific IgM antibody, showing that WTA-specific IgM plays a critical role in conferring protection against S. aureus infection.

Above: a) Complement deposition on wild type (WT) S. aureus or SpA-deficient (Δspa) S. aureus, pre-opsonized with either WTA-specific IgM or IgG. Note that IgG requires a much higher concentration than IgM to deposit the same amount of complement protein. b) Relative complement deposition on SpA-deficient S. aureus, pre-opsonized with either WTA-specific IgM or IgG in the presence of various concentrations of recombinant SpA. Note that IgG is inhibited by increasing concentrations of SpA, while IgM is unaffected. c) Neutrophil killing of S. aureus in the presence of WTA-specific IgM, WTA-specific IgG, or no antibody control. Note that the % of bacteria survival in the presence of IgG is not significantly different from bacteria with no antibody present, whereas IgM results in significantly fewer bacteria that survived. d) Spleen CFU counts from mice at 24 h post-infection. Mice have been passively immunized with either WTA-specific IgM, anti-TNP IgM (as an isotype control), or a PBS control. Mice that were given a control (either PBS or control antibody) had more bacteria in their spleens than mice that received a WTA-specific IgM treatment. Each of these experiments demonstrates that IgM is effective against S. aureus bacteria.

WTA-specific IgM antibodies were reduced in human ICU patients with S. aureus bacteremia

The researchers also tested a cohort of 36 ICU patients with S. aureus bacteremia. They observed that IgG responses to any of the three WTA glycotypes were comparable between healthy donors and patients with bacteremia. However, the patients infected with S. aureus had significantly reduced WTA-specific IgM when compared to healthy donors or patients infected with Streptococcus pyogenes. In addition, IgM levels against the TarS and TarM glycotypes of WTA were significantly lower in deceased patients than in those who recovered.

 

Conclusion

This research sheds light on the crucial role of WTA-specific IgM antibodies in protection against S. aureus infections. The study’s findings challenge the conventional focus on IgG antibodies and suggest that efforts to boost durable opsonic IgM responses through vaccination may hold promise in preventing severe S. aureus infections. The identification of WTA-specific IgM as a significant protective factor can inform risk stratification for hospitalized patients and guide the design of antibody-based therapies and vaccines against this major human pathogen.

What I liked about this preprint

This preprint caught my attention because of its focus on IgM antibodies, which are often overlooked in favor of the more differentiated IgG antibodies. With the rising challenge of antibiotic-resistant bacteria, it is crucial to explore alternative treatment methods and vaccination strategies.

Questions for the authors

  1. Was there any correlation between the site of S. aureus infection and patient IgM levels?
  2. Do you have any hypotheses as to why patient IgM levels were decreased in patients with S. aureus bacteremia but not S. pyogenes bacteremia?
  3. It looks as though the TarP glycotype may be less affected by IgM treatment than the TarS or TarM glycotypes. Do you have a hypothesis as to why this might be the case? Does this have implications for the effectiveness of a future WTA-specific IgM-based treatment?

Tags: antibodies, staphylococcus aureus

doi: https://doi.org/10.1242/prelights.35297

Read preprint (No Ratings Yet)

Have your say

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Sign up to customise the site to your preferences and to receive alerts

Register here

Also in the immunology category:

Alzheimer’s Disease Patient Brain Extracts Induce Multiple Pathologies in Vascularized Neuroimmune Organoids for Disease Modeling and Drug Discovery

Yanru Ji, Xiaoling Chen, Meek Connor Joseph, et al.

Selected by 07 November 2024

Manuel Lessi

Neuroscience

Global coordination of protrusive forces in migrating immune cells

Patricia Reis-Rodrigues, Nikola Canigova, Mario J. Avellaneda, et al.

Selected by 10 October 2024

yohalie kalukula

Biophysics

Integrin conformation-dependent neutrophil slowing obstructs the capillaries of the pre-metastatic lung in a model of breast cancer

Frédéric Fercoq, Gemma S. Cairns, Marco De Donatis, et al.

Selected by 07 October 2024

Simon Cleary

Cancer Biology

Also in the microbiology category:

Green synthesized silver nanoparticles from Moringa: Potential for preventative treatment of SARS-CoV-2 contaminated water

Adebayo J. Bello, Omorilewa B. Ebunoluwa, Rukayat O. Ayorinde, et al.

Selected by 14 November 2024

Safieh Shah, Benjamin Dominik Maier

Epidemiology

Intracellular diffusion in the cytoplasm increases with cell size in fission yeast

Catherine Tan, Michael C. Lanz, Matthew Swaffer, et al.

Selected by 18 October 2024

Leeba Ann Chacko, Sameer Thukral

Cell Biology

Significantly reduced, but balanced, rates of mitochondrial fission and fusion are sufficient to maintain the integrity of yeast mitochondrial DNA

Brett T. Wisniewski, Laura L. Lackner

Selected by 30 August 2024

Leeba Ann Chacko

Cell Biology

preLists in the immunology category:

Journal of Cell Science meeting ‘Imaging Cell Dynamics’

This preList highlights the preprints discussed at the JCS meeting 'Imaging Cell Dynamics'. The meeting was held from 14 - 17 May 2023 in Lisbon, Portugal and was organised by Erika Holzbaur, Jennifer Lippincott-Schwartz, Rob Parton and Michael Way.

 



List by Helen Zenner

Fibroblasts

The advances in fibroblast biology preList explores the recent discoveries and preprints of the fibroblast world. Get ready to immerse yourself with this list created for fibroblasts aficionados and lovers, and beyond. Here, my goal is to include preprints of fibroblast biology, heterogeneity, fate, extracellular matrix, behavior, topography, single-cell atlases, spatial transcriptomics, and their matrix!

 



List by Osvaldo Contreras

Single Cell Biology 2020

A list of preprints mentioned at the Wellcome Genome Campus Single Cell Biology 2020 meeting.

 



List by Alex Eve

Autophagy

Preprints on autophagy and lysosomal degradation and its role in neurodegeneration and disease. Includes molecular mechanisms, upstream signalling and regulation as well as studies on pharmaceutical interventions to upregulate the process.

 



List by Sandra Malmgren Hill

Antimicrobials: Discovery, clinical use, and development of resistance

Preprints that describe the discovery of new antimicrobials and any improvements made regarding their clinical use. Includes preprints that detail the factors affecting antimicrobial selection and the development of antimicrobial resistance.

 



List by Zhang-He Goh

Zebrafish immunology

A compilation of cutting-edge research that uses the zebrafish as a model system to elucidate novel immunological mechanisms in health and disease.

 



List by Shikha Nayar
Close